Monday February 9, 2026
Across regulation, AI adoption, and supply chain strategy, this week’s news highlights how early decisions — and untested assumptions — tend to shape outcomes long before execution begins.
8 things to watch this week:
1. ⚖️ Medtronic ordered to pay $382M in anticompetitive surgical device lawsuit
A federal jury found Medtronic liable for anticompetitive conduct tied to its surgical device business, awarding $382M in damages. The ruling underscores growing scrutiny around pricing strategy, bundling, and channel control — risks that often remain invisible until they become expensive.
Medical Device Network
2. 🧠 Before You Execute, Pressure-Test the Commercial Story
RŌG Health works with medtech leaders to surface hidden assumptions that derail commercialization — often long before execution makes those risks costly.
Our proprietary Commercial Launch Impact Framework — or CLIF Analysis — is one way we do that: a fast, external review of your pitch, website, and public materials to identify where the story is clear, where it relies on assumptions, and where gaps could create downstream risk with customers, partners, or investors.
3. 🧠 FDA clears Median Technologies’ lung nodule evaluation software
The FDA has cleared Median’s AI-driven software for lung nodule assessment, reinforcing momentum in regulated imaging analytics. As AI moves deeper into diagnostics, regulatory readiness is increasingly a competitive advantage — not just a hurdle.
Medical Device Network
4. 🦠 UV-Smart receives FDA 510(k) clearance for TEE probe disinfection system
UV-Smart’s D60 system secured FDA clearance for automated TEE probe disinfection, addressing infection control in high-risk procedures. Products that reduce clinical risk while improving workflow efficiency continue to resonate with hospital buyers.
Business Wire
5. 🤝 Axena Health and Mayo Clinic expand pelvic health collaboration
Axena Health and Mayo Clinic are expanding their collaboration to advance digital pelvic health solutions. Strategic provider partnerships remain one of the clearest ways to validate emerging categories and accelerate adoption.
MPO
6. 🧾 Medical simulation market projected to reach $7.23B by 2030
The global medical simulation market is expected to see steady growth through 2030, driven by clinician training demands and workforce shortages. Simulation is increasingly viewed as operational infrastructure, not optional tooling.
PR Newswire / MarketsandMarkets
7. 🤖 As AI enters the OR, reports surface of surgical errors and misidentification
New reports detail cases where AI-assisted surgical tools contributed to misidentified anatomy and procedural errors. As adoption accelerates, governance, validation, and accountability are becoming as important as performance claims.
OODA Loop
8. 🌍 The medical device industry grapples with tariffs and supply chain pressure
Tariffs and trade uncertainty are forcing device manufacturers to reassess sourcing, pricing, and margin strategy. For leadership teams, supply chain resilience is now a core strategic concern — not just an operational one.
Medical Economics
Bonus story:
🇺🇸 PulseNmore builds U.S. momentum following FDA clearance
PulseNmore is expanding U.S. commercial engagement following FDA clearance for its remote ultrasound technology. It’s a reminder that regulatory wins only matter when paired with disciplined go-to-market execution.
PR Newswire
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.